ArticleWellcome open research2023

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.

Mainga Hamaluba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.